Background

Dr. Parker earned her medical degree with honors in 2004 from Kirov State Medical Academy, Russia. She completed her training in ophthalmology and served as a primary care ophthalmologist in Russia before moving to the United States. She started her research career in 2010 as a post-doctoral fellow at OHSU Casey Eye Institute, where she worked under the supervision of J. Timothy Stout, M.D., and designed and managed pre-clinical trials and projects to develop lentiviral based gene therapy for prevention of corneal rejection and retinal disorders associated with retinal neovascularization. In 2014, as a senior researcher, she joined the Casey Reading Center. She is a certified reader for the reading center, and she has led and contributed to a number of research projects that have furthered understanding of how to utilize ophthalmological testing to assess safety and efficacy in gene therapy trials.

Current research

Dr. Parker's research interests include ophthalmic genetics, gene therapy for retinal and corneal pathologies, ocular imaging, and development and validation of novel parameters for use in clinical trials. 

Publications

Test-Retest Variability of Functional and Structural Parameters in Patients with Stargardt disease. TVST, 2016 Oct; 5(5). Residual Foveal Cone Structure in CNGB3-associated Achromatopsia. IOVS August 2016. Structure-Function Modeling of Optical Coherence Tomography and Standard Automated Perimetry in the Retina of Patients with Autosomal Dominant Retinitis Pigmentosa. PLoS ONE. Feb, 2016 Suppression of Neovascularization of Donor Corneas by Transduction with Equine Infection Anemia Virus-based Lentiviral Vectors Expressing Endostatin and Angiostatin. Human Gene Therapy, January 2014. EncorStat (R), a highly effective Equine Infectious Anaemia Virus-based lentiviral gene therapy to prevent corneal graft rejection. Human Gene Therapy. Oct, 2011. Prospidinum Cloridum as a new therapy for the wet form of age-related macular degeneration. Vestnik OGU Russia, Dec. 2007.